

List of Publications by Year
in descending order

Source: <https://exaly.com/author-pdf/684794/publications.pdf>

Version: 2024-02-01

189
papers

20,353
citations

18482

62
h-index

11052

137
g-index

197
all docs

197
docs citations

197
times ranked

26516
citing authors

#	ARTICLE	IF	CITATIONS
1	TIM-3 blockade enhances IL-12-dependent antitumor immunity by promoting CD8 ⁺ T cell and XCR1 ⁺ dendritic cell spatial co-localization. , 2022, 10, e003571.		13
2	TGF- β -mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures. Immunity, 2022, 55, 115-128.e9.	14.3	62
3	Interaction of bacterial genera associated with therapeutic response to immune checkpoint PD-1 blockade in a United States cohort. Genome Medicine, 2022, 14, 35.	8.2	29
4	Genomic and Single-Cell Landscape Reveals Novel Drivers and Therapeutic Vulnerabilities of Transformed Cutaneous T-cell Lymphoma. Cancer Discovery, 2022, 12, 1294-1313.	9.4	18
5	IgA-Dominated Humoral Immune Responses Govern Patients' Outcome in Endometrial Cancer. Cancer Research, 2022, 82, 859-871.	0.9	21
6	Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T α cells. Cancer Cell, 2022, 40, 545-557.e13.	16.8	53
7	Tumor Intrinsic PD-L1 Promotes DNA Repair in Distinct Cancers and Suppresses PARP Inhibitor-Induced Synthetic Lethality. Cancer Research, 2022, 82, 2156-2170.	0.9	23
8	Tumor Expression Quantitative Trait Methylation Screening Reveals Distinct CpG Panels for Deconvolving Cancer Immune Signatures. Cancer Research, 2022, 82, 1724-1735.	0.9	6
9	Racial Differences in the Tumor Immune Landscape and Survival of Women with High-Grade Serous Ovarian Carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1006-1016.	2.5	6
10	Expression of epigenetic pathway related genes in association with PD-L1, ER/PgR and MLH1 in endometrial carcinoma. PLoS ONE, 2022, 17, e0264014.	2.5	1
11	Pharmacologic Tumor PDL1 Depletion with Cefepime or Ceftazidime Promotes DNA Damage and Sensitivity to DNA-Damaging Agents. International Journal of Molecular Sciences, 2022, 23, 5129.	4.1	4
12	Olfactory Receptor OR2H1 Is an Effective Target for CAR T Cells in Human Epithelial Tumors. Molecular Cancer Therapeutics, 2022, 21, 1184-1194.	4.1	12
13	T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma. , 2022, 10, e004512.		14
14	β T cells share the spotlight in cancer. Nature Cancer, 2022, 3, 657-658.	13.2	4
15	Barriers and Opportunities for CAR T-Cell Targeting of Solid Tumors. Immunological Investigations, 2022, 51, 2215-2225.	2.0	5
16	Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 109, 425-435.	0.8	35
17	IgA transcytosis and antigen recognition govern ovarian cancer immunity. Nature, 2021, 591, 464-470.	27.8	99
18	The prognostic and predictive implications of the 12-chemokine score in muscle invasive bladder cancer.. Journal of Clinical Oncology, 2021, 39, 466-466.	1.6	2

#	ARTICLE	IF	CITATIONS
19	Methyltransferase inhibitors restore SATB1 protective activity against cutaneous T cell lymphoma in mice. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	6
20	Circulating Biomarkers of Inflammation and Ovarian Cancer Risk in the Nurses' Health Studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 710-718.	2.5	9
21	CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from $\hat{\pm}$ PD-L1 and include tissue-selective $\hat{\beta}$ T cell activation. , 2021, 9, e002051.		12
22	Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway. <i>Molecular Therapy</i> , 2021, 29, 1541-1556.	8.2	20
23	Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. <i>Blood</i> , 2021, 137, 2621-2633.	1.4	137
24	The 12-CK Score: Global Measurement of Tertiary Lymphoid Structures. <i>Frontiers in Immunology</i> , 2021, 12, 694079.	4.8	10
25	Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer. <i>Nature Reviews Urology</i> , 2021, 18, 543-555.	3.8	20
26	The Cancer Epitope Database and Analysis Resource: A Blueprint for the Establishment of a New Bioinformatics Resource for Use by the Cancer Immunology Community. <i>Frontiers in Immunology</i> , 2021, 12, 735609.	4.8	10
27	Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. <i>Nature Medicine</i> , 2021, 27, 1410-1418.	30.7	168
28	Clinical characteristics and prognostic factors of 70 patients with SÃ©zary syndrome: a single-institutional experience at Moffitt cancer center. <i>Leukemia and Lymphoma</i> , 2021, , 1-8.	1.3	1
29	B cells and cancer. <i>Cancer Cell</i> , 2021, 39, 1293-1296.	16.8	52
30	Cover Image, Volume 60, Issue 2. <i>Molecular Carcinogenesis</i> , 2021, 60, i.	2.7	0
31	Wide and deep learning for automatic cell type identification. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 1052-1062.	4.1	8
32	Effects of checkpoint kinase 1 inhibition by prexasertib on the tumor immune microenvironment of head and neck squamous cell carcinoma. <i>Molecular Carcinogenesis</i> , 2021, 60, 138-150.	2.7	11
33	PD-L1 Expression Correlates With Young Age and CD8+ TIL Density in Poorly Differentiated Cervical Squamous Cell Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2020, 39, 428-435.	1.4	14
34	Humoral immune responses: Unsung heroes of the war on cancer. <i>Seminars in Immunology</i> , 2020, 49, 101419.	5.6	11
35	Sirt2 Inhibition Enhances Metabolic Fitness and Effector Functions of Tumor-Reactive T Cells. <i>Cell Metabolism</i> , 2020, 32, 420-436.e12.	16.2	72
36	CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade. <i>Cancer Research</i> , 2020, 80, 5063-5075.	0.9	21

#	ARTICLE	IF	CITATIONS
37	COX-Prostaglandin Pathway Inhibition May Augment the Effects of Immunotherapy in Breast Cancer. Journal of the American College of Surgeons, 2020, 231, S34-S35.	0.5	0
38	BTN3A1 governs antitumor responses by coordinating $\hat{1}\hat{2}$ and $\hat{3}\hat{4}$ T cells. Science, 2020, 369, 942-949.	12.6	83
39	Loss of $\langle \text{microRNA} \rangle$ $\hat{21}$ leads to profound stromal remodeling and short survival in $\langle \text{K}\hat{\text{R}}\text{as} \rangle$ -driven mouse models of pancreatic cancer. International Journal of Cancer, 2020, 147, 2265-2278.	5.1	14
40	Kindlin $\hat{3}$ gives patrolling monocytes a strong grip. Journal of Leukocyte Biology, 2020, 107, 879-881.	3.3	0
41	Cancer Moonshot Immuno-Oncology Translational Network (IOTN): accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer. , 2020, 8, e000796.		7
42	The Association of $\langle \text{MUC16} \rangle$ Mutation with Tumor Mutation Burden and Its Prognostic Implications in Cutaneous Melanoma. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1792-1799.	2.5	15
43	Effects of Tobacco Smoking on the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2020, 26, 1474-1485.	7.0	62
44	The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling. Immunity, 2020, 52, 668-682.e7.	14.3	107
45	68 $\hat{\dots}$ The prognostic and predictive implications of the 12-chemokine score in muscle invasive bladder cancer. , 2020, , .		1
46	Abstract CT056: Durable complete responses to adoptive cell transfer using tumor infiltrating lymphocytes (TIL) in non-small cell lung cancer (NSCLC): A phase I trial. Cancer Research, 2020, 80, CT056-CT056.	0.9	14
47	c-Maf: a bad influence in the education of macrophages. Journal of Clinical Investigation, 2020, 130, 1629-1631.	8.2	11
48	Abstract 5719: Tumor-suppressive stromal activity of pro-fibrogenic microRNA-21 in initiation and progression of K-Ras-driven mouse models of pancreatic cancer. , 2020, , .		0
49	93 $\hat{\dots}$ Targeting sirt2 rescues the metabolic fitness and effector functions of tumor-reactive T cells within the metabolically restricted tumor microenvironment. , 2020, , .		0
50	280 $\hat{\dots}$ Both tumor intrinsic and extrinsic factors contribute to TIL resistance in lung cancer patients. , 2020, , .		0
51	AMPK Alpha-1 Intrinsically Regulates the Function and Differentiation of Tumor Myeloid-Derived Suppressor Cells. Cancer Research, 2019, 79, 5034-5047.	0.9	37
52	Estimation of immune cell content in tumor using single-cell RNA-seq reference data. BMC Cancer, 2019, 19, 715.	2.6	32
53	Exosomes Produced by Mesenchymal Stem Cells Drive Differentiation of Myeloid Cells into Immunosuppressive M2-Polarized Macrophages in Breast Cancer. Journal of Immunology, 2019, 203, 3447-3460.	0.8	126
54	Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. Cancer Cell, 2019, 35, 885-900.e10.	16.8	475

#	ARTICLE	IF	CITATIONS
55	Illuminating the Numbers: Integrating Mathematical Models to Optimize Photomedicine Dosimetry and Combination Therapies. <i>Frontiers in Physics</i> , 2019, 7, .	2.1	3
56	ER stress-induced mediator C/EBP homologous protein thwarts effector T α cell activity in tumors through T-bet repression. <i>Nature Communications</i> , 2019, 10, 1280.	12.8	83
57	Effect of cyclical intermittent hypoxia on Ad5CMVCre induced solitary lung cancer progression and spontaneous metastases in the KrasG12D+; p53fl/fl; myristolated p110fl/fl ROSA-gfp mouse. <i>PLoS ONE</i> , 2019, 14, e0212930.	2.5	12
58	Immunologic Consequences of Sequencing Cancer Radiotherapy and Surgery. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-16.	2.1	16
59	IL-33 delays metastatic peritoneal cancer progression inducing an allergic microenvironment. <i>OncolImmunology</i> , 2019, 8, e1515058.	4.6	14
60	Breaking barriers for T cells by targeting the EPHA2/TGF- β 2/COX-2 axis in pancreatic cancer. <i>Journal of Clinical Investigation</i> , 2019, 129, 3521-3523.	8.2	13
61	Trial in progress: Phase II study of stereotactic body radiation therapy and atezolizumab in the management of recurrent, persistent, or metastatic cervical cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS5596-TPS5596.	1.6	2
62	CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity. <i>Nature Communications</i> , 2018, 9, 631.	12.8	72
63	Frontline Science: Microbiota reconstitution restores intestinal integrity after cisplatin therapy. <i>Journal of Leukocyte Biology</i> , 2018, 103, 799-805.	3.3	72
64	Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. <i>Cell Reports</i> , 2018, 22, 3393-3400.	6.4	77
65	Inhibition of Human Dendritic Cell ER Stress Response Reduces T Cell Alloreactivity Yet Spares Donor Anti-tumor Immunity. <i>Frontiers in Immunology</i> , 2018, 9, 2887.	4.8	19
66	IRE1 α -XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity. <i>Nature</i> , 2018, 562, 423-428.	27.8	252
67	Dysregulated Microbial Fermentation of Soluble Fiber Induces Cholestatic Liver Cancer. <i>Cell</i> , 2018, 175, 679-694.e22.	28.9	344
68	Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. <i>Clinical Cancer Research</i> , 2018, 24, 5347-5356.	7.0	253
69	PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer. <i>Integrative Cancer Science and Therapeutics</i> , 2018, 5, .	0.1	38
70	Abstract SY01-02: Blockade of estrogen signaling boosts antitumor immunity by dwindling cancer-promoting myelopoiesis. , 2018, , .		0
71	Targeted Therapy and Immunosuppression in the Tumor Microenvironment. <i>Trends in Cancer</i> , 2017, 3, 19-27.	7.4	57
72	SATB1 Expression Governs Epigenetic Repression of PD-1 in Tumor-Reactive T Cells. <i>Immunity</i> , 2017, 46, 51-64.	14.3	122

#	ARTICLE	IF	CITATIONS
73	Immunotherapy for Breast Cancer: Current and Future Strategies. Current Surgery Reports, 2017, 5, 1.	0.9	31
74	Characterization of Novel Immune Checkpoint Receptors within the Breast Cancer Tumor Microenvironment. Journal of the American College of Surgeons, 2017, 225, S21.	0.5	0
75	ARID1A-mutated ovarian cancers depend on HDAC6 Activity. Nature Cell Biology, 2017, 19, 962-973.	10.3	173
76	Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer. Cancer Immunology Research, 2017, 5, 1152-1161.	3.4	309
77	Tumor Cell-Independent Estrogen Signaling Drives Disease Progression through Mobilization of Myeloid-Derived Suppressor Cells. Cancer Discovery, 2017, 7, 72-85.	9.4	153
78	Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target. Clinical Cancer Research, 2017, 23, 441-453.	7.0	77
79	Estrogens drive myeloid-derived suppressor cell accumulation. Oncoscience, 2017, 4, 5-6.	2.2	5
80	Abstract 3707: Tumor-associated neutrophils with antigen-presenting features in early-stage human lung cancer. , 2017, , .		0
81	Origin and Role of a Subset of Tumor-Associated Neutrophils with Antigen-Presenting Cell Features in Early-Stage Human Lung Cancer. Cancer Cell, 2016, 30, 120-135.	16.8	311
82	Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer. Signal Transduction and Targeted Therapy, 2016, 1, .	17.1	83
83	Shaping the Immune Landscape in Cancer by Galectin-Driven Regulatory Pathways. Journal of Molecular Biology, 2016, 428, 3266-3281.	4.2	67
84	State-of-the-art of regulatory dendritic cells in cancer. , 2016, 164, 97-104.		43
85	Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma. Cancer Research, 2016, 76, 6964-6974.	0.9	294
86	The Primary Effect on the Proteome of ARID1A-mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-transcriptional Level. Molecular and Cellular Proteomics, 2016, 15, 3348-3360.	3.8	23
87	BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression. Cell Reports, 2016, 16, 2829-2837.	6.4	331
88	Constitutively activated PI3K accelerates tumor initiation and modifies histopathology of breast cancer. Oncogenesis, 2016, 5, e267-e267.	4.9	28
89	BET Inhibitors Suppress ALDH Activity by Targeting <i>ALDH1A1</i> Super-Enhancer in Ovarian Cancer. Cancer Research, 2016, 76, 6320-6330.	0.9	115
90	Trametinib Drives T-cell-Dependent Control of KRAS-Mutated Tumors by Inhibiting Pathological Myelopoiesis. Cancer Research, 2016, 76, 6253-6265.	0.9	46

#	ARTICLE	IF	CITATIONS
91	Galectinâ€1 is essential for the induction of MOG_{35â€55}-based intravenous tolerance in experimental autoimmune encephalomyelitis. European Journal of Immunology, 2016, 46, 1783-1796.	2.9	24
92	IL15 Agonists Overcome the Immunosuppressive Effects of MEK Inhibitors. Cancer Research, 2016, 76, 2561-2572.	0.9	26
93	Satb1 Overexpression Drives Tumor-Promoting Activities in Cancer-Associated Dendritic Cells. Cell Reports, 2016, 14, 1774-1786.	6.4	89
94	Local Hyperthermia Treatment of Tumors Induces CD8+ T Cell-Mediated Resistance Against Distal and Secondary Tumors. Frontiers in Nanobiomedical Research, 2016, , 309-347.	0.1	3
95	Abstract IA32: Commensal microorganisms and polymorphic mucosal surfaces determine the evolution of distal metastatic tumors. , 2016, , .		0
96	Abstract A02: The origin and role of APC-like hybrid tumor-associated neutrophils in early-stage human lung cancer. , 2016, , .		0
97	Myristoylated p110Î± Causes Embryonic Death Due to Developmental and Vascular Defects. Open Life Sciences, 2015, 10, 461-478.	1.4	5
98	ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis. Cell, 2015, 161, 1527-1538.	28.9	639
99	The Tumor Macroenvironment. Advances in Cancer Research, 2015, 128, 235-262.	5.0	48
100	Small but Mighty: Selected Commensal Bacterial Species Determine the Effectiveness of Anti-cancer Immunotherapies. Immunity, 2015, 43, 1037-1039.	14.3	2
101	Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nature Medicine, 2015, 21, 231-238.	30.7	530
102	Molecular adjuvant IL-33 enhances the potency of a DNA vaccine in a lethal challenge model. Vaccine, 2015, 33, 4313-4320.	3.8	33
103	TLR5 signaling, commensal microbiota and systemic tumor promoting inflammation: the three parcae of malignant progression. Oncoimmunology, 2015, 4, e1021542.	4.6	7
104	Telomeric repeat-containing RNA (TERRA) constitutes a nucleoprotein component of extracellular inflammatory exosomes. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E6293-300.	7.1	76
105	Microbially Driven TLR5-Dependent Signaling Governs Distal Malignant Progression through Tumor-Promoting Inflammation. Cancer Cell, 2015, 27, 27-40.	16.8	242
106	Size does not matter: commensal microorganisms forge tumor-promoting inflammation and anti-tumor immunity. Oncoscience, 2015, 2, 239-246.	2.2	9
107	Abstract A66: Tumor-associated neutrophils in early stage human lung cancer are not immunosuppressive, but exhibit an inflammatory phenotype and provide accessory signals for T cell activation. , 2015, , .		0
108	Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. Journal of Clinical Investigation, 2014, 124, 5466-5480.	8.2	483

#	ARTICLE	IF	CITATIONS
109	Mesothelin expression is associated with poor outcomes in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 675-684.	2.5	42
110	Local hyperthermia treatment of tumors induces CD8+ T cell-mediated resistance against distal and secondary tumors. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2014, 10, 1273-1285.	3.3	156
111	Fibroblast activation protein, a potential diagnostic and therapeutic target for cancerâ€”reply. <i>Human Pathology</i> , 2014, 45, 1553-1554.	2.0	4
112	Transforming Growth Factor β -Mediated Suppression of Antitumor T Cells Requires FoxP1 Transcription Factor Expression. <i>Immunity</i> , 2014, 41, 427-439.	14.3	100
113	Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer. <i>Journal of Visualized Experiments</i> , 2014, , .	0.3	20
114	Reprogramming immune responses via microRNA modulation. <i>MicroRNA Diagnostics and Therapeutics</i> , 2014, 1, .	0.0	5
115	Mesothelin expression as a predictive biomarker of breast cancer outcomes.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11119-11119.	1.6	0
116	Avirulent <i>Toxoplasma gondii</i> Generates Therapeutic Antitumor Immunity by Reversing Immunosuppression in the Ovarian Cancer Microenvironment. <i>Cancer Research</i> , 2013, 73, 3842-3851.	0.9	86
117	A role for the chemokine receptor CCR6 in mammalian sperm motility and chemotaxis. <i>Journal of Cellular Physiology</i> , 2013, 229, n/a-n/a.	4.1	49
118	Fibroblast activation protein expression by stromal cells and tumor-associated macrophages in human breast cancer. <i>Human Pathology</i> , 2013, 44, 2549-2557.	2.0	75
119	Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition. <i>Cell Cycle</i> , 2013, 12, 2113-2119.	2.6	74
120	Phagocytes mediate targeting of iron oxide nanoparticles to tumors for cancer therapy. <i>Integrative Biology (United Kingdom)</i> , 2013, 5, 159-171.	1.3	42
121	Pathological Mobilization and Activities of Dendritic Cells in Tumor-Bearing Hosts: Challenges and Opportunities for Immunotherapy of Cancer. <i>Frontiers in Immunology</i> , 2013, 4, 435.	4.8	23
122	Editorial: A clear vision needs some balance. <i>Journal of Leukocyte Biology</i> , 2012, 92, 918-920.	3.3	0
123	Does the β F508-CFTR mutation induce a proinflammatory response in human airway epithelial cells?. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2012, 303, L509-L518.	2.9	28
124	Good things come in small packages. <i>Oncolmmunology</i> , 2012, 1, 968-970.	4.6	11
125	Reprogramming Tumor-Associated Dendritic Cells <i>In Vivo</i> Using miRNA Mimetics Triggers Protective Immunity against Ovarian Cancer. <i>Cancer Research</i> , 2012, 72, 1683-1693.	0.9	137
126	Modulating the tumor immune microenvironment as an ovarian cancer treatment strategy. <i>Expert Review of Obstetrics and Gynecology</i> , 2012, 7, 413-419.	0.4	16

#	ARTICLE	IF	CITATIONS
127	Mast cells impair the development of protective anti-tumor immunity. Cancer Immunology, Immunotherapy, 2012, 61, 2273-2282.	4.2	39
128	Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. Journal of Experimental Medicine, 2012, 209, 495-506.	8.5	273
129	Formation of telomeric repeat-containing RNA (TERRA) foci in highly proliferating mouse cerebellar neuronal progenitors and medulloblastoma. Journal of Cell Science, 2012, 125, 4383-94.	2.0	58
130	Anti-tumor immunity: Myeloid leukocytes control the immune landscape. Cellular Immunology, 2012, 278, 21-26.	3.0	19
131	Targeting the Tumor Stroma as a Novel Treatment Strategy for Breast Cancer. Advances in Pharmacology, 2012, 65, 45-61.	2.0	53
132	Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Cancer Research and Treatment, 2012, 133, 799-804.	2.5	123
133	Double Agents in the War on Cancer: Leukocytes Govern Ovarian Cancer Progression. Oncotarget, 2012, 3, 226-227.	1.8	2
134	It never rains but it pours. Cell Cycle, 2011, 10, 368-369.	2.6	5
135	Fluorescence-Based Codetection with Protein Markers Reveals Distinct Cellular Compartments for Altered MicroRNA Expression in Solid Tumors. Clinical Cancer Research, 2010, 16, 4246-4255.	7.0	102
136	Harnessing the Effect of Adoptively Transferred Tumor-Reactive T Cells on Endogenous (Host-Derived) Antitumor Immunity. Clinical and Developmental Immunology, 2010, 2010, 1-11.	3.3	5
137	CD4+ T Cells Elicit Host Immune Responses to MHC Class II α^* Ovarian Cancer through CCL5 Secretion and CD40-Mediated Licensing of Dendritic Cells. Journal of Immunology, 2010, 184, 5654-5662.	0.8	75
138	<i>Mycobacterium tuberculosis</i> infection induces <i>il12rb1</i> splicing to generate a novel IL-12 β 1 isoform that enhances DC migration. Journal of Experimental Medicine, 2010, 207, 591-605.	8.5	44
139	<i>Mycobacterium tuberculosis</i> infection induces <i>il12rb1</i> splicing to generate a novel IL-12 β 1 isoform that enhances DC migration. Journal of Experimental Medicine, 2010, 207, 897-897.	8.5	0
140	Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes. Cell Cycle, 2010, 9, 260-268.	2.6	41
141	CD277 is a Negative Co-stimulatory Molecule Universally Expressed by Ovarian Cancer Microenvironmental Cells. Oncotarget, 2010, 1, 329-338.	1.8	62
142	Abstract LB-360: Fluorescence-based co-registration with protein markers reveals distinct cellular compartments for altered microRNA expression in solid tumors. , 2010, , .		0
143	ORIGINAL ARTICLE: Human Uterine NK Cells Interact with Uterine Macrophages via NKG2D upon Stimulation with PAMPs. American Journal of Reproductive Immunology, 2009, 61, 52-61.	1.2	26
144	<i>In situ</i> Stimulation of CD40 and Toll-like Receptor 3 Transforms Ovarian Cancer-Infiltrating Dendritic Cells from Immunosuppressive to Immunostimulatory Cells. Cancer Research, 2009, 69, 7329-7337.	0.9	124

#	ARTICLE	IF	CITATIONS
145	CCL5-Mediated Endogenous Antitumor Immunity Elicited by Adoptively Transferred Lymphocytes and Dendritic Cell Depletion. <i>Cancer Research</i> , 2009, 69, 6331-6338.	0.9	56
146	Nanomolecular targeting of dendritic cells for ovarian cancer therapy. <i>Future Oncology</i> , 2009, 5, 1189-1192.	2.4	19
147	Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. <i>Journal of Translational Medicine</i> , 2009, 7, 49.	4.4	56
148	Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. <i>Journal of Clinical Investigation</i> , 2009, 119, 2231-44.	8.2	177
149	Inflammatory and immune responses induced by nanomaterials: challenges and opportunities for future nanotherapies. <i>Nanotechnology Perceptions</i> , 2009, 5, 195-203.	0.2	1
150	Estradiol regulates MICA expression in human endometrial cells. <i>Clinical Immunology</i> , 2008, 129, 325-332.	3.2	19
151	Depletion of Dendritic Cells Delays Ovarian Cancer Progression by Boosting Antitumor Immunity. <i>Cancer Research</i> , 2008, 68, 7684-7691.	0.9	105
152	PILAR is a novel modulator of human T-cell expansion. <i>Blood</i> , 2008, 112, 1259-1268.	1.4	37
153	Role of Vascular Leukocytes in Ovarian Cancer Neovascularization. , 2008, 622, 273-280.		11
154	Estradiol induces NKG2D ligand expression in human endometrial epithelium. <i>FASEB Journal</i> , 2008, 22, 853.10.	0.5	1
155	Scavenger Receptor-Targeted Leukocyte Depletion Inhibits Peritoneal Ovarian Tumor Progression. <i>Cancer Research</i> , 2007, 67, 4783-4789.	0.9	85
156	Chimeric NKG2D Receptor-Bearing T Cells as Immunotherapy for Ovarian Cancer. <i>Cancer Research</i> , 2007, 67, 5003-5008.	0.9	96
157	Vascular Leukocytes: a Population with Angiogenic and Immunossuppressive Properties Highly Represented in Ovarian Cancer. , 2007, 590, 185-193.		20
158	Preparation of apoptotic tumor cells with replication-incompetent HSV augments the efficacy of dendritic cell vaccines. <i>Cancer Gene Therapy</i> , 2006, 13, 182-193.	4.6	24
159	Use of immuno-LCM to identify the in situ expression profile of cellular constituents of the tumor microenvironment. <i>Cancer Biology and Therapy</i> , 2006, 5, 635-642.	3.4	60
160	Direct vaccination with tumor cells killed with ICP4-deficient HSVd120 elicits effective antitumor immunity. <i>Cancer Biology and Therapy</i> , 2006, 5, 867-874.	3.4	20
161	Vascular leukocytes contribute to tumor vascularization. <i>Blood</i> , 2005, 105, 679-681.	1.4	183
162	The role of dendritic cell precursors in tumour vasculogenesis. <i>British Journal of Cancer</i> , 2005, 92, 1182-1187.	6.4	108

#	ARTICLE	IF	CITATIONS
163	Oncolytic HSV Exerts Direct Antiangiogenic Activity in Ovarian Carcinoma. Human Gene Therapy, 2005, 16, 765-778.	2.7	81
164	HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer. Molecular Therapy, 2005, 12, 789-802.	8.2	119
165	Immunotherapy for gynaecological malignancies. Expert Opinion on Biological Therapy, 2005, 5, 1193-1210.	3.1	31
166	Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Medicine, 2004, 10, 942-949.	30.7	4,442
167	Tumor-infiltrating dendritic cell precursors recruited by a β -defensin contribute to vasculogenesis under the influence of Vegf-A. Nature Medicine, 2004, 10, 950-958.	30.7	431
168	Ovarian Carcinoma Expresses the NKG2D Ligand Letal and Promotes the Survival and Expansion of CD28 ⁺ Antitumor T Cells. Cancer Research, 2004, 64, 2175-2182.	0.9	64
169	Oncolytic HSV Exerts Direct Antiangiogenic Activity in Ovarian Carcinoma. Journal of Immunotherapy, 2004, 27, S7.	2.4	0
170	Antioxidant nutrients protect against cyclosporine A nephrotoxicity. Toxicology, 2003, 189, 99-111.	4.2	108
171	Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer. New England Journal of Medicine, 2003, 348, 203-213.	27.0	2,930
172	Isolation and biochemical characterization of LEAP β 2, a novel blood peptide expressed in the liver. Protein Science, 2003, 12, 143-152.	7.6	161
173	Distribution of new human β -defensin genes clustered on chromosome 20 in functionally different segments of epididymis. Genomics, 2003, 81, 175-183.	2.9	104
174	LETAL, A Tumor-Associated NKG2D Immunoreceptor Ligand, Induces Activation and Expansion of Effector Immune Cells. Cancer Biology and Therapy, 2003, 2, 446-451.	3.4	55
175	T Cells in Ovarian Cancer. New England Journal of Medicine, 2003, 348, 1814-1814.	27.0	1
176	Generation of a Syngeneic Mouse Model to Study the Effects of Vascular Endothelial Growth Factor in Ovarian Carcinoma. American Journal of Pathology, 2002, 161, 2295-2309.	3.8	129
177	Different Effects of Glucose Starvation on Expression and Stability of VEGF mRNA Isoforms in Murine Ovarian Cancer Cells. Biochemical and Biophysical Research Communications, 2002, 292, 860-868.	2.1	65
178	NK-1 receptor gene expression is related to pain in chronic pancreatitis. Pain, 2001, 91, 209-217.	4.2	88
179	Real-Time Quantitative PCR of Telomerase mRNA Is Useful for the Differentiation of Benign and Malignant Pancreatic Disorders. Pancreas, 2001, 22, 331-340.	1.1	25
180	Identification of a novel, multifunctional β -defensin (human β -defensin 3) with specific antimicrobial activity. Cell and Tissue Research, 2001, 306, 257-264.	2.9	371

#	ARTICLE	IF	CITATIONS
181	Structure determination of human and murine beta-defensins reveals structural conservation in the absence of significant sequence similarity. Protein Science, 2001, 10, 2470-2479.	7.6	115
182	Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. International Journal of Cancer, 2000, 88, 12-20.	5.1	130
183	Macrophages infiltrating the tissue in chronic pancreatitis express the chemokine receptor CCR5. Surgery, 2000, 128, 806-814.	1.9	64
184	Interference of Chylomicrons in Analysis of Platelets by Flow Cytometry. Thrombosis Research, 1998, 91, 49-52.	1.7	13
185	Increased Hydrogen Peroxide Formation in Polymorphonuclear Leukocytes of IDDM Patients. Diabetes Care, 1998, 21, 326-327.	8.6	14
186	CYCLOSPORINE INCREASES LOCAL GLOMERULAR SYNTHESIS OF REACTIVE OXYGEN SPECIES IN RATS1. Transplantation, 1998, 66, 1325-1329.	1.0	55
187	Interference from lipemia in cell count by hematology analyzers. Clinical Chemistry, 1996, 42, 987-988.	3.2	22
188	Evaluation of zone electrophoresis of serum proteins performed on the Helena Laboratories rapid electrophoresis analyser. Scandinavian Journal of Clinical and Laboratory Investigation, 1995, 55, 729-731.	1.2	2
189	SATB1 Expression Governs Follicular Helper T-cell-Triggered Tertiary Lymphoid Structure Assembly. SSRN Electronic Journal, 0, , .	0.4	0